| Follow us on Twitter |
Population demographics and efforts by managed care providers to control healthcare costs are driving the growth in drug self-administration, particularly for chronic conditions, introducing a new class of naïve users to parenteral drug delivery. User-friendly syringe and injection device designs and the availability of an increasing number of drugs in pre-filled insertable and disposable cartridges are propelling the growth of prefilled syringes across all user segments.
Improved patient compliance, efficient delivery of high-priced biologicals, and patient & caregiver safety are key market drivers in this sector. The cost of biologicals such as recombinant proteins has created interest in prefilled syringes to reduce cost and waste associated with the handling of vial-packaged drugs. Partnerships between device designers and drug developers are an essential element in the success of prefilled devices, particularly for patient self-administration.
These findings are contained in a new and comprehensive report: Prefilled Syringes: Drugs, Devices and Disease Therapeutics. The report analyzes eleven important prefilled syringe therapeutic segments including chronic diseases such as diabetes, autoimmune disorders, and hormone replacement, as well as drugs for oncology, blood factors, reproductive health, wellness programs and vaccine administration.
More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical and healthcare technology consulting firm providing services in strategic planning, venture development, product commercialization, and technology and market assessment.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org
Source: Greystone Associates
Posted February 19th, 2008 by mksmith
